Date:1/26/2009

nts for 2007, excluding (1) certain of the restructuring charges (see (b) above), (2) certain components of the write-off of inventory (see (i) above), (3) the write- off of the acquired IPR&D related to the Alantos and Ilypsa acquisitions (see (l) above), (4) the write-off of the cost of a semi-completed manufacturing asset (see (k) above), and (5) the tax benefit recognized as a result of resolving certain non-routine transfer pricing issues with the IRS (see (p) above). (r) The following table presents the computations for GAAP and "Adjusted" diluted earnings per share, computed under the treasury stock method. "Adjusted" earnings per share presented below excludes stock option expense: Three months ended Three months ended December 31, 2008 December 31, 2007 ----------------- ----------------- GAAP "Adjusted" GAAP "Adjusted" ---- ---------- ---- ---------- Income (Numerator): Net income for basic and diluted EPS $961 $1,124 $835 $1,088 ==== ====== ==== ====== Shares (Denominator): Weighted-average shares for basic EPS 1,055 1,055 1,087 1,087 Effect of dilutive securities 6 6 (*) 5 4 (*) --- --- --- --- Weighted-average shares for diluted EPS 1,061 1,061 1,092 1,091 ===== ===== ===== ===== Diluted earnings per share $0.91 $1.06 $0.76 $1.00
'/>"/>

SOURCE Amgen Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Related biology technology :

1. Beckman Coulter Announces Fourth Quarter 2008 Earnings to be Released on Monday, February 9, 2009, After Market Closes
2. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
3. Caliper Life Sciences Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
4. Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
5. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
6. BioMed Realty Trust Declares Fourth Quarter 2008 Common Stock and Preferred Stock Dividends
7. Martek Announces Fourth Quarter and FY 2008 Financial Results
8. Martek to Announce Fourth Quarter and Fiscal Year 2008 Results
9. Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
10. Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year
11. Varian, Inc. Reports Strong Fourth Quarter 2008 Results